One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry

Ohashi, Yasuo; Ikeda, Masataka; Kunitoh, Hideo; Sasako, Mitsuru; Okusaka, Takuji; Mukai, Hirofumi; Nakamura, Mashio; Oba, Mari S.; Kimura, Takeshi; Ibusuki, Kei; Takita, Atsushi; Sakon, Masato

doi:10.1016/j.thromres.2021.09.012

Cited by 18 publications

(30 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, VTE frequency in patients with colorectal cancer was lower than that in patients with pancreatic cancer. 25,29 Nonetheless, the frequency of VTE in Japanese patients with colorectal cancer in this study (6.4% at the time of cancer diagnosis and 1.0% for composite VTE during the 1-year follow-up period) is noticeably higher than that in the general Japanese population. A recent analysis of a medical claims database (n = 5,106,151)…”

Section: Risk Factors For Composite Vte During the Follow-up Periodcontrasting

confidence: 56%

“…Patients receiving oral anticoagulant treatment that started before enrollment was factor with a HR <1 (HR: 0.37, 95% CI: 0.05-2.83; p = 0.337). 29 We have previously reported that the overall study results of the Cancer-VTE Registry show that VTE prevalence at the time of cancer diagnosis was 5.9%, and symptomatic VTE in the 1-year follow-up period was 0.5%. Furthermore, VTE frequency in patients with colorectal cancer was lower than that in patients with pancreatic cancer.…”

Section: Risk Factors For Composite Vte During the Follow-up Periodmentioning

confidence: 90%

See 1 more Smart Citation

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)

et al. 2022

Self Cite

View full text Add to dashboard Cite

The impact of venous thromboembolism in Japanese colorectal cancer patients has not been elucidated. This prespecified subanalysis of the Cancer‐VTE Registry aimed to report venous thromboembolism and event data after 1 year of follow‐up in 2477 patients with colorectal cancer and investigate risk factors of venous thromboembolism. Of 2477 patients, 158 (6.4%) had venous thromboembolism in venous thromboembolism screening at enrollment. Asymptomatic distal deep‐vein thrombosis accounted for 123/158 (77.8%) of venous thromboembolism cases. During the follow‐up period, symptomatic, incidental events requiring treatment and composite venous thromboembolism incidences were 0.3%, 0.8%, and 1.0%, respectively. The incidence of bleeding events, cerebral infarction/transient ischemic attack/systemic embolic event, and all‐cause death were 1.0%, 0.3%, and 4.8%, respectively. These results were consistent with the main study results. In multivariable analysis, venous thromboembolism at baseline was a risk factor of composite venous thromboembolism during the follow‐up period. Japanese patients with colorectal cancer and advancing cancer stage before treatment had more frequent venous thromboembolism complications at baseline, higher incidence of venous thromboembolism events during cancer treatment, and higher mortality.

show abstract

Section: Risk Factors For Composite Vte During the Follow-up Periodcontrasting

confidence: 56%

Section: Risk Factors For Composite Vte During the Follow-up Periodmentioning

confidence: 90%

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The previously reported overall study results of the Cancer-VTE Registry revealed that VTE prevalence at the time of cancer diagnosis was 5.9% and symptomatic VTE at the 1-year follow-up period was 0.5%. 20,21 In our subanalysis of patients with lung cancer, the incidence of VTE at baseline and during follow-up was as low as in the main study. Differences in race, VTE screening, disease severity, and treatment characteristics may explain the low VTE incidence in the present study.…”

Section: Discussionmentioning

confidence: 53%

“…32,33 These results also suggest that VTE, even if asymptomatic before cancer therapy, was associated with a higher incidence of each event, including death, during multiple cancer therapies, which is also consistent with the main study results. 20 Remarkable progress has been made in the development of therapeutic agents for lung cancer in recent years, and the range of systemic therapies available to physicians has expanded. 34,35 Some anticancer drugs, platinum drugs, [11][12][13][14] ICIs, 16 and anti-vascular endothelial growth factor agents 15 reportedly increase thrombus formation and predispose the patient to develop VTE.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the Registry explored the incidence and risk factors of clinical events during 1 year of follow-up. [20][21][22] The objective of the present subanalysis of data from the Japanese Cancer-VTE Registry was to investigate outcomes relating to VTE, bleeding, embolic events, and allcause death after 1 year of follow-up in the cohort of patients with lung cancer. In addition, this subanalysis aimed to investigate the potential risk factors associated with these events.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis)

Awano

Okano

Kawachi

et al. 2022

JTO Clinical and Research Reports

Self Cite

View full text Add to dashboard Cite

Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort

Okusaka,

Saiura,

Shimada

et al. 2023

J Gastroenterol

View full text Add to dashboard Cite

Background This substudy of the Cancer-VTE Registry estimated venous thromboembolism (VTE) incidence and risk factors in pancreatic cancer patients. Methods The Cancer-VTE Registry was an observational study that collected VTE data from patients with solid tumors across Japan. We measured baseline VTE prevalence, and at 1-year follow-up, the cumulative incidence of symptomatic and composite VTE (symptomatic VTE and incidental VTE requiring treatment), bleeding, cerebral infarction/transient ischemic attack (TIA)/systemic embolic event (SEE), and all-cause death. Results Of 1006 pancreatic cancer patients, 86 (8.5%) had VTE at baseline, and seven (0.7%) had symptomatic VTE. Significant risk factors of baseline VTE were Eastern Cooperative Oncology Group performance status (ECOG PS) of 1, body mass index (BMI) ≥ 25 kg/m2, history of VTE, D-dimer > 1.2 µg/mL, and hemoglobin < 10 g/dL. At 1-year follow-up, the cumulative incidence of events was higher for pancreatic cancer vs other cancers. Pancreatic cancer patients with VTE vs those without VTE had significantly higher incidences of bleeding, cerebral infarction/TIA/SEE, and all-cause death. No significant risk factors for composite VTE were identified. Conclusions The cumulative incidence of composite VTE during cancer treatment was higher in pancreatic cancer than in other cancer types. Some risk factors for VTE prevalence at cancer diagnosis were identified. Although VTE prevalence at cancer diagnosis did not predict the subsequent 1-year incidence of composite VTE, it was a significant predictor of other events such as all-cause death in pancreatic cancer patients. Trial registration UMIN Clinical Trials Registry; UMIN000024942

show abstract

One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry

Cited by 18 publications

References 63 publications

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)

One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis)

Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort

Contact Info

Product

Resources

About